mTOR signalling is commonly activated in cancer which has led to the generation of a number of mTORC1 inhibitors (rapalogs) that have demonstrated clinical efficacy in a subset of cancers including relapsed renal cell carcinoma [46] and postmenopausal hormone-receptor-positive breast cancer [47]. Here, MTOR is linked to hereditary clear cell renal cell carcinoma.